DR ANTHONY MELVIN CRASTO,WorldDrugTracker, helping millions, A 90 % paralysed man in action for you, I am suffering from transverse mylitis and bound to a wheel chair,With death on the horizon, This will not stop me, Gods call only..........
DR ANTHONY MELVIN CRASTO Ph.D ( ICT, Mumbai) , INDIA 29Yrs Exp. in the feld of Organic Chemistry,Working for GLENMARK PHARMA at Navi Mumbai, INDIA. Serving chemists around the world. Helping them with websites on Chemistry.Million hits on google, world acclamation from industry, academia, drug authorities for websites, blogs and educational contribution

Tuesday, 30 December 2014

Dr. Farzad Kobarfard

Dr. Farzad Kobarfard
Prof. of Medicinal Chemistry
Shahid Beheshti Univ. Med. Sci.
 
Farzad Kobarfard
Shams Alley, Vali-e-Asr Ave.
Tehran, Iran
+9821-8820-0092 (w)
+9821-8805-7163 (h)
+912-343-4595 (mobile)
farzadkf@yahoo.com
farzadkobarfard@sbmu.ac.ir
IRAN Tehran to Valie Asr Ave, Alley Takhti خيابان وليعصر خيابان تختي پله ششم

Valie Asr Ave, Alley Takhti خيابان وليعصر خيابان تختي پله ششم


Teheran

EDUCATION
1995-2000 University of The Sciences in Philadelphia (USP), PA, USA
● Ph.D. degree in Medicinal Chemistry
● GPA: 4.00
● Research Advisor: Professor Joel M. Kauffman
● Dissertation: Synthesis and Evaluation of new fluorinated potentialAntimicrobial drugs

1982-1988 Tehran University of Medical Sciences, Tehran, Iran
● Pharmacy Doctorate
● GPA: 3.85
Teheran

WORK EXPERIENCES
2007-present
Associate professor, Department of Medicinal Chemistry,Shaheed Beheshti School of Pharmacy, Tehran, Iran
Map of School of Pharmacy Shahid Beheshti University
2001-2007Assistant professor, Department of Medicinal Chemistry,
Shaheed Beheshti School of Pharmacy, Tehran, Iran
2004-presentTechnical Director of Iran Doping Control Laboratory, Tehran,Iran
2001-present Member of editorial board of Iran Pharmacopoeia
2002-present Member of editorial board of Iranian Journal of Pharmaceutical
Research (IJPR)
2000-2001 Assistant professor, University of The Sciences in Philadelphia (USP),
Philadelphia, PA, USA
2000-2001 Adjunct Faculty member in Philadelphia Community College
(PCC) Philadelphia, PA, USA
1995-2000 Teaching assistant, University of The Sciences in Philadelphia (USP),
Philadelphia, PA, USA
1991-1995 Instructor, Shaheed Beheshti School of Pharmacy, Tehran, Iran
1989-1991 Member of Editorial Board for the book "Generic Drugs of Iran"Darou-Pakhsh Pharmaceutical Co., Tehran, Iran

SPECIAL COURSES & TRAINING
Current Screening Methods in Doping Analysis
Gas Chromatography-Mass Spectrometry
Liquid Chromatography-Mass Spectrometry
Solid Phase Extraction Methods
Computational Chemistry
Combinatorial Chemistry
Modern NMR Specroscopy
AWARDS
Abraham Glasser predoctoral research fellowship, University of The
Sciences in Philadelphia (USP), Philadelphia, PA, 1999
Student Recognition Award, American Association of Iranian
Pharmaceutical Scientists (ASIPS), San Francisco, CA, 1998
Graduate Studies Scholarship, Shaheed Beheshti University of
Medical Sciences, Tehran, Iran, 1995

Ruins of the Achaemenid palace ofPersepolis, now a UNESCO World Heritage Site

PUBLICATIONS
Books:
1. Principles and Applications of LC-Mass (Farsi)
2. Psychotropic Compounds (Farsi)
3. Prohibited Substances in Sport (Farsi) 4. Iran National Formulary (member of Editorial board)
5. Iranian Pharmacopoeia (Member of Editorial Board)


Modern impression of Achaemenidcylinder seal, 5th century BCE. A winged solar disc legitimises the Persian king who subdues two rampant Mesopotamian lamassu figures.
LANGUAGE SKILLS
English Language, writing properly and speaking fluently
Farsi, native language

Persian miniature depicting Timur's campaign in India
PROFESSIONAL AFFILIATIONS
American Chemical Society (ACS)
American Association of Pharmaceutical Scientists (AAPS)
Iranian Association of Pharmaceutical Scientists (IAPS)

Nadir Shah was the founder of the Afsharid dynasty.
PATENTS
Halogenated Antituberculosis Agents, Farzad Kobarfard, Joel M.Kauffman, United State Patent 6,482,982, Nov. 19, 2002
Halogenated Antituberculosis Agents, Farzad Kobarfard,
Two new lathyrane type diterpenoids fromEuphorbia aelleniiA. M. Ayatollahi, M. Ghanadian, S. Afshrypour, M. I. Choudhari, F.Kobarfard, M. Rahmati Fitoterapia, 2010, X, XXX

Ayatollah Khomeini returns to Iran after 14 years exile on 1 February 1979.
Papers:
● Antiglycation activity of Otostegia persica (Burm.) Boiss S. A. Ayatollahi, F. Kobarfard, J. Asgarpanah, M. I. Choudhari
African Journal of Biotechnology, 2010, 9 (24), 3645
● Heavy metal contamination of table sult consumed in Iran A. M. Cheraghali, F. Kobarfard, N. Faeizy, Iranian Journal of
Pharmaceutical research, 2010, 9 (2), 129
● Development and optimization of solid lipid nanoparticles of amikacin by central composite designJ. Arshosaz, S. Ghafari, M. R. Khoshayand, F. Atyabi, S. Azarmi, F. Kobarfard, Journal of Liposome Research, 2010, 20 (2), 97.
● Preclinical pharmacokinetics of KBF611, a new antituberculosis agent in mice and rabbits and comparison with
thiacetazone F. M. Shahab, F. Kobarfard, S. Dadashzadeh Xenobiotica, 2009, 1, 10
● Terpenes from aerial parts of Euphorbia splendida S. A. Ayatollahi, A. Shojai, F. Kobarfard, M. Nori, M. Fathi, M. I.
Choudhari, Jornla of Medicinal Plants Research, 2008, 3 (9), 660
● Assessment of endogenous androgen levels in meat, liver,and testis of Iranian native cross-bread male sheep and bull by GCmass
spectrometry R. Ahmadkhani, F. Kobarfard, N. Rastkari, M. Khoshayand, M.Amini, A. Shafiee, Food Additive and Contaminants, 2009, 26 (4),453.
● Quantification of endogenous steroids in human urine by gcmass spectrometry using a surrogate analyte approach.
R. Ahmadkhani, A. Shafiee, N. Rastkari, M. Khoshayand, F.Kobarfard, Journal of Chromatography B, 2010, 878, 845.
● Serum copper alterations in pulmonary tuberculosis patients under treatment with ethambutol.
M. A. Nazari, F. Kobarfard, P. Tabarsi, J. Salamzadeh, Biological Trace Element Research, 2009, 128, 161
● Two Fravones from Salvia lerifolia S. A. Ayatollahi, A. Shojai, F. Kobarfard, M. Mohammadzadeh, M.
I. Choudhari, Iranian Journal of Pharmaceutical Research, 2009, 8 (3), 179.
● Simultaneous determination of a new antituberculosis agent KBF-611 and its deacetylated metabolite in mouse and rabbit
plasma by HPLC: Application to preclinical pharmacokinetics F. Mostafavi Shahab, F. Kobarfard, S. Dadashzadeh, Archives of
Pharmaceutical Research, 2009, 1
● Ion release and pH of a new endodontic cement, MTA and Portland cement
S. A. Gazvini, M. A. Tabrizi, F. Kobarfard, A. Akbarzadeh, S. Asgarim, Iranian Journal of Endodontics, 2009, 4 (2), 74
● Accurate quantification of endogenous androgenic steroids in cattle’s meat by gas chromatography mass spectrometry using a
surrogate analyte approach R. Ahmadkhaniha, a. Shafiee, N. Rastkari, F. Kobarfard
Analytica Chimica Acta ,xx, 2008
● Flavonoids from Iris songarica and their antioxidant and esterogenic activity
M. R. Moein, S. I. Khan, Z. Ali, S. A. M. Ayatollahi, F. Kobarfard, S. Nasim. M. I. Choudhary, I. A. Khan
Planta Medica , 74, 1492, 2008
● Synthesis and evaluation of invitro anti-tuberculosis activity of N-substituted glycolamides F. Daryaee, F. Kobarfard, A. Khalaj, P. Farnia European Journal of Medicinal Chemistry ,xx, 1, 2008
● Correlation between different lipophilicity parameters and antimycobacterial activities of 2-hydroxyacetamides F. Kobarfard, A. Khalaj, F. Daryaee, A. Z. Larijany, S. Rezaee aru ,16, 2 ,xx, 2008
● 99mTc-HMPAO-labeled liposome: an investigation into the effect of some formulation factors on labeling efficiency
and in vitro stability N. Mirahmadi, M. H. Babai, A. M. Vali, F. Johari Daha, F. Kobarfard, S. Dadashzadeh
Nuclear Medicine and Biology ,35,387, 2008
● Chemical Constituents from Otostegia persica S. A. Ayatollahi, F. Kobarfard, J. Asgarpanah, Z. Ahmed
J. Chem. Soc. Pak ,29, 1,61, 2007
● Lysosomal oxidative stress cytotoxicity induced by dacarbazine and its pyridine derivative in hepatocytes J. Pourahmad, F. Kobarfard, Marzieh Amirmostofian Iranian J. Pharmaceutical Sci., 2, 4, 123, 2006
● An improved GC method for rapid analysis of valproic acid in human plasma without derivatization R. Ahmadkhaniha, N. Rastkari, F. Kobarfard, H. Pakdaman,O. Ahmadkhaniha, A. Kebriaizadeh Iranian J. Pharmaceutical Sci., 2, 5, 25, 2006
● Electrochemical Study of 3,4-dihydroxybenzoic acid in the presence of 4-hydroxy-1-methyl-2(1H)-quinolone: Application to
electrochemical synthesis of new benzofuran derivative. A. Bayandori Moghadam, F. Kobarfard, S. S. H. Davarani, D.
Nematollahi, M. Shamsipour, A. R. Fakhari Journal of Electrochemical Chemistry, 586, 161, 2006
● Introducing a full Validated analytical procedure as an official compendial method for fentanyl transdermal patches
A. Mehdizadeh, T. Toliyat, M. R. Rouini, F. Kobarfard Daru, 13, 46, 2005
● Mechanistic study of electrochemical oxidation of o-dihydroxybenzenes in the presence of 4-hydroxy-1-methyl-
2(1H)-quinolon, Application to the electrochemical synthesis A. Bayandori Moghaddam, F. kobarfard, A. R. Fakhari, D. Nematollahi, S. S. H. Davarani Electrochimica Acta, 51, 739, 2005
● Effect of Cultivation conditions on growth and antifungal activity Mycena leptocephala H. Vahidi, F. Kobarfard, F. Namjoyan
African Journal of Biotechnology, 3(11)606, 2004
● 1D and 2D-NMR assignments of Nigricin from Iris imbricate S. A. M. Ayatollahi, M. R. Moein, F. Kobarfard, S. Nasim,
M. I. Choudhary Iranian Journal of Pharmaceutical research, 4, 250, 2005
● Synthesis and antimycobacterial activity of 2-hydroxyacetamides F. Daryaee, F. Kobarfard, A. Khalaj, P. Farnia
Daru, 13(3)94, 2005
● Lysosomal oxidative stress cytotoxicity induced by p-phenylenediamine redox cycling in hepatocytese J. Pourahmad, F. Kobarfard, A. Shakoori. Iranian Journal of Pharmaceutical Research, 4, 193, 2004
● Two isoflavones from Iris songorica Schrenk A. M. Ayatollahi, M. R. Moein, F. Kobarfard, M. I. Coudhary
Daru, 12, 54, 2004
● Is FT-ATR a sensitive tool for determination of aflatoxins? A. Shmsai, F. Kobarfard, H. Yazdanpanah, O. Sabzevari
Journal of American Oil Chemists Society, 81, 719, 2004
● Attempted syntheses of aminofluorothiophenes F. Kobarfard, J. M. Kauffman, W. J. Boyko Journal of Heterocyclic Chemistry, 36(5)1247, 1999
● The chemical constitutions of Potamogeton pectinatus S. A. M. Ayatollahi, F. Kobarfard, H. Komeylizadeh, N. Kashani,
N. Afza, A. Malik Pak. J. Sci. Ind. Res. 40, 90, 1998
● The protective effect of liquorice and its derivatives against gastric ulcer induced by piroxicam and mefenamic acid in rats
M. Zolfaghari, A. R. Dehpour, M. Amanlow, N. Azari, F. Kobarfard Pharmaceutical Sciences, 2(4)179, 1996
● Antiulcer activity of liquorice and its derivatives in experimental gastric lesions induced by ibuprofen in rats A. R. Dehpour, M. Zolfaghari, T. Samadian, F. Kobarfard, M. Faizi, M. Assari
International journal of pharmacutics, 119(2)133, 1995
Remarks in Successful Cellular Investigations for Fighting Breast Cancer Using Novel Synthetic Compounds
by Farshad H. Shirazi, Afshin Zarghi, Farzad Kobarfard, Rezvan Zendehdel, Maryam Nakhjavani, Sara Arfaiee, Tannaz Zebardast, Shohreh Mohebi, Nassim Anjidani, Azadeh Ashtarinezhad and Shahram Shoeibiin the book "Breast Cancer - Focusing Tumor Microenvironment, Stem cells and Metastasis" edited by Mehmet Gunduz and Esra Gunduz, ISBN 978-953-307-766-6, InTech, December 12, 2011
IRAN

Mount Damavand, Iran's highest point, is located in Amol County,Mazanderan.

Posted by at 1 comment:
Labels: , ,

Sunday, 28 December 2014

Bryan K. S. Yeung.....Profile

 Bryan Yeung

Bryan K. S. Yeung
Novartis Institute for Tropical Diseases, 10 Biopolis Road, #05-01 Chromos, Singapore 
Associate Director, Malaria Program at Novartis Institute for Tropical Diseases
 SINGAPORE


Involved in programme for antimalarial shown below

http://newdrugapprovals.org/2014/12/27/nitd609/http://newdrugapprovals.org/2014/12/27/nitd609/

Spirotetrahydro β-Carbolines (Spiroindolones): A New Class of Potent and Orally Efficacious Compounds for the Treatment of Malaria

Bryan K. S. Yeung, et al
 *To whom correspondence should be addressed. Phone: +65 6722 2923. Fax: +65 6722 2918. E-mail: bryan.yeung@novartis.com.

Journal of Medicinal Chemistry, 2010 ,  vol. 53,   14  p. 5155 – 5164
http://pubs.acs.org/toc/jmcmar/53/14



 NIBR LOGO 146x50

 SINGAPORE FLAG

Profile

Bryan K S Yeung - ResearchGate

www.researchgate.net/profile/Bryan_Yeung
Researcher » Bryan K S Yeung, Novartis, Novartis Institute for Tropical Diseases (NITD), Singapore, Medicinal Chemistry and Organic Chemistry.

Bryan K S Yeung - Publications - ResearchGate

www.researchgate.net/profile/Bryan_Yeung/publications
Paul W Smith, Thierry T Diagana, Bryan K S Yeung. [Show abstract] [Hide abstract] ABSTRACT: SUMMARY The number of novel antimalarial candidates ...

Bryan Yeung profiles | LinkedIn

https://www.linkedin.com/pub/dir/Bryan/Yeung
View the profiles of professionals named Bryan Yeung on LinkedIn. There are 16 professionals named Bryan Yeung, who use LinkedIn to exchange information, ...
 
 ABOUT
The Novartis Institute for Tropical Disease (NITD) is a Singapore-based tropical disease research institute created through a public-private partnership between Novartis and the Singapore Economic Development Board. Research at NITD focuses primarily on developing novel small molecule therapies for tropical infectious diseases that are endemic to the developing world, particularly dengue fever, malaria and tuberculosis.[1][2]

History and mission

NITD was founded in 2002 as a public-private partnership between Swiss-based pharmaceutical company Novartis and the Singapore Economic Development Board.[1]
NITD states its goals are "to discover novel treatments and prevention methods for major tropical diseases." Their website states they hope to have at least two drug candidates going through clinical trials in patients by the year 2012.[2]
Novartis has also stated that the NITD will seek to make treatments developed by the NITD available without profit to the poor in developing nations in which these diseases are endemic.[3]

Research

NITD is a small molecule drug discovery research institute.[1]
Research is currently focused on three main diseases:[2]
NITD's research model relies on global partnership with other research institutes.[1] In 2008, NITD announced a 5-year collaborative research effort would be conducted in cooperation with the TB Alliance to develop new medicines for tuberculosis, including drug resistant tuberculosis.[4]

Education

In addition to research, NITD is engaged in educational activities. It runs a research-based Master of Science program in fields related to infectious diseases in cooperation with National University of Singapore, University of Basel and Swiss Tropical Institute.[5]
NITD also supports training opportunities for post-graduate students and post-doctoral fellows.[2]

Fighting neglected infectious diseases

NITD Scientist
NIBR LOGO 146x50
The Novartis Institute for Tropical Diseases (NITD), one of the institutes of the Novartis Institutes for BioMedical Research (NIBR), is dedicated to finding new medicines to treat neglected, infectious diseases. As a small-molecule drug discovery research institute, it combines the drug-discovery expertise and cutting-edge technologies of Novartis to fight infectious tropical diseases, including Dengue fever, Human African Trypanomiasis and Malaria among others.
In developing countries where these diseases are endemic, Novartis will make treatments accessible to the communities that need them. NITD was set up as a public-private partnership between Novartis and the Singapore Economic Development Board (EDB) in 2002. Since then, it has grown to more than 100 researchers and supporting staff. As a major center of excellence for drug discovery, NITD will offer exceptional teaching and training opportunities for post-doctoral fellows and graduate students.
Contact NITD
Novartis Institute for Tropical Diseases Pte. Ltd.
10 Biopolis Road
#05-01 Chromos
Singapore 138670

 



EARLIER


Research Scientist II

Exelixis Inc
– (3 years 9 months) • Team member of phosphatidylinositol-3 kinase (PI3K) project that lead to a development candidate (XL765) currently in Phase Ib/2 trials.
• Design and synthesis of kinase inhibitors for use as anti-cancer agents
• Supervised an associate research scientist



 The Scripps Research Institute

The Scripps Research Institute

PostDoc, Chemistry
Synthesis and screening of a library of DNA binding agents based on analogs of distamycin A
Preparation of heterocyclic monomer building blocks for a library of DNA binding agents
Synthesis of isochrysohermidin-distamycin hybrids as new DNA binding agents

University of Illinois at Urbana-Champaign

Ph.D, Chemistry

University of Hawaii at Manoa

B.S., Chemistry




References

  1. "About NITD". Novartis AG. 2008. Retrieved 2008-12-23.
  2. "Our mission". Novartis AG. 2008. Retrieved 2008-12-23.
  3. "Commitment to Patients Earns Novartis' Dr. Daniel Vasella B'nai B'rith International's Highest Award". PharmaLive. Canon Communications Pharmaceutical Media Group. 2008-12-15. Retrieved 2008-12-23. Novartis has developed several programs aimed at enhancing affordability and access to treatment, including the Novartis Institute for Tropical Diseases, where Novartis researches novel treatments and prevention methods for neglected tropical diseases such as Dengue fever, and will make these available, without profit, to poor endemic countries.
  4. "Novartis symposium in Mozambique tackles emerging tuberculosis challenges" (media release). Basel, Switzerland: Novartis Global Communications. 2008-09-08. p. 5. Retrieved 2008-12-23. One of the core missions of the NITD is its commitment to improving access to medicines and helping reduce the overall global TB disease burden. The NITD recently announced a five-year research collaboration with the TB Alliance to develop new medicines for TB, including drug-resistant strains.
  5. "Master of Science in infectious diseases, vaccinology and drug discovery". Novartis AG. 2008. Retrieved 2008-12-23.[dead link]

External links



Patents by Inventor Bryan K. S. Yeung

Compounds and compositions for the treatment of parasitic diseases

Patent number: 8871754
Abstract: The present invention provides compounds of formula I: or a pharmaceutically acceptable salt, tautomer, or stereoisomer, thereof, wherein the variables are as defined herein. The present invention further provides pharmaceutical compositions comprising such compounds and methods of using such compounds for treating, preventing, inhibiting, ameliorating, or eradicating the pathology and/or symptomology of a disease caused by a Plasmodium parasite, such as malaria.
Type: Grant
Filed: November 18, 2013
Issued: October 28, 2014
Assignees: IRM LLC, Novartis AG
Inventors: Arnab Kumar Chatterjee, Advait Suresh Nagle, Prasuna Paraselli, Ravinder Reddy Kondreddi, Seh Yong Leong, Pranab Kumar Mishra, Robert Joseph Moreau, Jason Thomas Roland, Wei Lin Sandra Sim, Oliver Simon, Liying Jocelyn Tan, Bryan K S Yeung, Bin Zou, Venkatataiah Bollu

Pyrazole kinase modulators and methods of use

Patent number: 8710038
Abstract: The present invention provides compounds for modulating protein kinase enzymatic activity for modulating cellular activities such as proliferation, differentiation, programmed cell death, migration and chemoinvasion. Compounds of the invention inhibit, regulate and/or modulate kinases. Methods of using the compounds and pharmaceutical compositions thereof to treat kinase-dependent diseases and conditions are also an aspect of the invention.
Type: Grant
Filed: September 15, 2005
Issued: April 29, 2014
Assignee: Exelixis, Inc.
Inventors: Tae-Gon Baik, Chris A. Buhr, Sunghoon Ma, John M. Nuss, Zerom Tesfai, Longcheng Wang, Bryan K. S. Yeung

Organic compounds

Patent number: 8399453
Abstract: The invention relates to organic compounds which have interesting pharmaceutical properties. In particular, the compounds are useful in the treatment and/or prevention of infections such as those caused by Plasmodium falciparum, Plasmodium vivax, Plasmodium malariae, Plasmodium ovale, Trypanosoma cruzi and parasites of the Leishmania genus such as, for example. Leishmania donovani. The invention also relates to pharmaceutical compositions containing the compounds, as well as processes for their preparation.
Type: Grant
Filed: July 19, 2011
Issued: March 19, 2013
Assignee: Novartis AG
Inventors: Shi Hua Ang, Philipp Krastel, Seh Yong Leong, Liying Jocelyn Tan, Wei Lin Josephine Wong, Bryan K. S. Yeung, Bin Zou

Pyridopyrimidinone inhibitors of PI3K? for the treatment of cancer

Patent number: 8247408
Abstract: The invention is directed to Compounds of Formula I and pharmaceutically acceptable salts or solvates thereof, as well as methods of making and using the compounds.
Type: Grant
Filed: October 9, 2006
Issued: August 21, 2012
Assignee: Exelixis, Inc.
Inventors: Tae-Gon Baik, Chris A. Buhr, Katherine Lara, Sunghoon Ma, Longcheng Wang, Bryan K. S. Yeung

ORGANIC COMPOUNDS

Application number: 20110275613
Abstract: The invention relates to organic compounds which have interesting pharmaceutical properties. In particular, the compounds are useful in the treatment and/or prevention of infections such as those caused by Plasmodium falciparum, Plasmodium vivax, Plasmodium malariae, Plasmodium ovale, Trypanosoma cruzi and parasites of the Leishmania genus such as, for example. Leishmania donovani. The invention also relates to pharmaceutical compositions containing the compounds, as well as processes for their preparation.
Type: Application
Filed: July 19, 2011
Issued: November 10, 2011
Assignee: NOVARTIS AG
Inventors: Shi Hua ANG, Philipp KRASTEL, Seh Yong LEONG, Liying Jocelyn TAN, Wei Lin Josephine WONG, Bryan K.S. YEUNG, Bin ZOU

Substituted pyrido[2,3-d]pyrimidin-7(8H)-one inhibitors of phospatidylinositol 3-kinase alpha

Patent number: 8044062
Abstract: The invention is directed to Compounds of Formula I: and pharmaceutically acceptable salts or solvates thereof, as well as methods of making and using the compounds.
Type: Grant
Filed: October 9, 2006
Issued: October 25, 2011
Assignee: Exelixis, Inc.
Inventors: Tae-Gon Baik, Chris A. Buhr, Katherine Lara, Sunghoon Ma, Morrison Mac, John M. Nuss, Longcheng Wang, Yong Wang, Bryan K. S. Yeung

Pyridopyrimidinone Inhibitors of PI3Kalpha

Application number: 20110237608
Abstract: The invention is directed to Compounds of Formula I: and pharmaceutically acceptable salts or solvates thereof, as well as methods of making and using the compounds.
Type: Application
Filed: June 2, 2011
Issued: September 29, 2011
Assignee: Exelixis, Inc.
Inventors: Tae-Gon Baik, Chris A. Buhr, Katherine Lara, Sunghoon Ma, Morrison Mac, John M. Nuss, Longcheng Wang, Yong Wang, Bryan K.S. Yeung

PYRIDO [2, 3-D] PYRIMIDIN-7-ONE COMPOUNDS AS INHIBITORS OF P13K-ALPHA FOR THE TREATMENT OF CANCER

Application number: 20100150827
Abstract: The invention is directed to a Compound of Formula I, II, or III. The invention provides compounds that inhibit, regulate, and/or modulate PI3K that are useful in the treatment of hyperproliferatives diseases, such as cancer.
Type: Application
Filed: April 11, 2008
Issued: June 17, 2010
Assignee: Exelixis, Inc
Inventors: Chris A. Buhr, William Bajjalieh, Anagha Abhijit Joshi, Katherine Lara, Sunghoon Ma, Charles K. Marlowe, Longcheng Wang, Bryan K.S. Yeung

ORGANIC COMPOUNDS

Application number: 20090275560
Abstract: The invention relates to organic compounds which have interesting pharmaceutical properties. In particular, the compounds are useful in the treatment and/or prevention of infections such as those caused by Plasmodium falciparum, Plasmodium vivax, Plasmodium malariae, Plasmodium ovale, Trypanosoma cruzi and parasites of the Leishmania genus such as, for example, Leishmania donovani. The invention also relates to pharmaceutical compositions containing the compounds, as well as processes for their preparation.
Type: Application
Filed: April 27, 2009
Issued: November 5, 2009
Assignee: NOVARTIS AG
Inventors: Shi Hua ANG, Philipp KRASTEL, Seh Yong LEONG, Liying Jocelyn TAN, Wei Lin Josephine WONG, Bryan K.S YEUNG, Bin ZOU

Pyridopyrimidinone Inhibitors of Pl3Kalpha

Application number: 20090270430
Abstract: The invention is directed to Compounds of Formula I: and pharmaceutically acceptable salts or solvates thereof, as well as methods of making and using the compounds.
Type: Application
Filed: October 9, 2006
Issued: October 29, 2009
Assignee: Exelixix, Inc.
Inventors: Tae-Gon Baik, Chris A. Buhr, Katherine Lara, Sunghoon Ma, Morrison Mac, John M. Nuss, Longcheng Wang, Yong Wang, Bryan K.S. Yeung

Azepinoindole Derivatives As Pharmaceutical Agents

Application number: 20090203577
Abstract: The present invention relates to compounds of formula I, which exhibit affinity for the farnesoid X receptor.
Type: Application
Filed: December 12, 2006
Issued: August 13, 2009
Assignee: EXELIXIS, INC.
Inventors: Tae-Gon Baik, Chris A. Buhr, Brett B. Busch, Diva Sze-Ming Chan, Brenton T. Flatt, Xiao-Hui Gu, Vasu Jammalamadaka, Richard George Khoury, Katherine Lara, Sunghoon Ma, Richard Martin, Raju Mohan, John M. Nuss, Jason Jevious Parks, Jason H. Wu, Bryan K. S. Yeung, Wei Xu, Tie-Lin Wang, Longcheng Wang

Pyridopyrimidinone inhibitors of pi3kalpha

Application number: 20090062274
Abstract: The invention is directed to Compounds of Formula I and pharmaceutically acceptable salts or solvates thereof, as well as methods of making and using the compounds.
Type: Application
Filed: October 9, 2006
Issued: March 5, 2009
Assignee: Exelixis, Inc
Inventors: Tae-Gon Baik, Chris A. Buhr, Katherine Lara, Sunghoon Ma, Longcheng Wang, Bryan K.S. Yeung




SINGAPORE PICS
 
 
 
 
Posted by at No comments:
Labels:
Subscribe to: Posts (Atom)